Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Specifically, sleepiness and dizziness may be enhanced.Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. For children 8 to 12 years old, the dose of dimenhydrinate liquid or tablets is 25 mg to 50 mg every 6 to 8 hours as needed to a maximum of 150 mg in a 24-hour period. Dimenhydrinate belongs to a group of medications called Dimenhydrinate works to relieve or prevent nausea and vomiting by affecting the vomiting centre in the brain. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. These agents should only be combined if alternative treatment options are inadequate. Larger doses of hyaluronidase may be required.HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. It works to relieve vertigo by affecting the brain and the inner ear. Not for OTC use in children <2 years of age.• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.Cannabidiol: May enhance the CNS depressant effect of CNS Depressants.Cannabis: May enhance the CNS depressant effect of CNS Depressants.Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. It is important to use this medication exactly as recommended by your doctor or pharmacist. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. [DSC] = Discontinued productDramamine: 50 mg [contains aspartame, fd&c yellow #6 aluminum lake]Extensive in the liver to metabolites (diphenyl-methoxy-ethylamine, diphenyl-methoxy-acetic, diphenyl-methoxy-N-methylamine) (Gravol Canadian labeling 2016)Antiemetic: IV: immediate; IM: 20 to 30 minutes; Oral: 15 to 30 minutes (Gravol Canadian labeling 2016)Data from a limited number of clinical trials suggest that dimenhydrinate may be beneficial for the treatment of nausea and vomiting of pregnancy (NVP) Based on the American College of Obstetricians and Gynecologists (ACOG) and the Society of Obstetricians and Gynaecologists of Canada practice guidelines, dimenhydrinate given for the treatment of NVP is an effective adjunct to doxylamine/pyridoxine in the management of this condition when doxylamine/pyridoxine alone does not provide symptom improvement Hypersensitivity to dimenhydrinate or any component of the formulation; neonates (injection contains benzyl alcohol) Oral: 50 to 100 mg every 4 to 6 hours (maximum: 400 mg/day) IM, IV: 50 mg every 4 hours; maximum: 100 mg every 4 hours Oral: 50 to 100 mg every 4 hours as necessary (maximum: 400 mg/day); Long acting formulation: 100 mg every 8 to 12 hours (maximum: 300 mg/day)Rectal: 50 to 100 mg every 6 to 8 hours as necessary Oral: 50 to 100 mg prior to procedure then 50 to 100 mg post-procedure; repeat as necessary (maximum: 400 mg/day) IM, IV: 50 mg prior to treatment then 50 mg post-procedure; repeat as necessary (maximum: 400 mg/day)IM, IV: 50 to 100 mg 30 to 60 minutes prior to treatment; 50 mg 1.5 and 3 hours after treatment.